# Lung 2023 Part 1 Case Scenario Answers

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Case 1 Answer sheet | | | | | | |
| Primary Site | **C34.0** | | Histology | | 8070/3 | |
| AJCC Stage | | | | | | |
| Clinical Stage | cT4 cN2 cM0 Stage 3B | | Pathological Stage | |  | |
| Regional Nodes Positive | | 95 | | | |
| Regional Nodes Examined | | 95 | | | |
| Date Regional Node Dissection | |  | | | |
| Dx Staging and Treatment | | | | | |
| Diagnostic Staging Procedure | | | | 02 | |
| Surgery of Primary Site | | | | 00 | |
| Scope of Regional Lymph Nodes | | | | 1 | |
| Surgical Procedure/Other Site | | | | 0 | |
| Systemic Therapy | | | | | |
| Chemotherapy | | | | 03 | |
| Immunotherapy | | | | 01 | |

|  |  |  |  |
| --- | --- | --- | --- |
| Radiation | | | |
| Phases | **I** | **II** | **III** |
| Primary Treatment Volume | 30 | 00 |  |
| Draining Lymph Nodes | 02 |  |  |
| Treatment Modality | 02 |  |  |
| External Beam Planning Technique | 05 |  |  |
| Dose Per Fraction (cGy) | 0200 |  |  |
| Number of Fractions | 030 |  |  |
| Total Dose (cGy) | 006000 |  |  |
| Date RT Started | 12/6/2022 | | |
| Date RT Ended | 1/16/2023 | | |
| # of Phases of RT to this Volume | 01 | | |
| RT Discontinued Early | 01 | | |
| Total Dose | 006000 | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Case 2 Answer sheet | | | | | | |
| Primary Site | **C34.1** | | Histology | | 8071/3 | |
| AJCC Stage | | | | | | |
| Clinical Stage | cT2b cN0 cM0 Stage 2A | | Pathological Stage | | pT3 pN0 cM0 Stage 2B | |
| Regional Nodes Positive | | 00 | | | |
| Regional Nodes Examined | | 21 | | | |
| Date Regional Node Dissection | | 1/9/23 | | | |
| Dx Staging and Treatment | | | | | |
| Diagnostic Staging Procedure | | | | 02 | |
| Surgery of Primary Site | | | | A330 | |
| Scope of Regional Lymph Nodes | | | | 5 | |
| Surgical Procedure/Other Site | | | | 0 | |
| Systemic Therapy | | | | | |
| Chemotherapy | | | | 03 | |
| Immunotherapy | | | | 00 | |

|  |  |  |  |
| --- | --- | --- | --- |
| Radiation | | | |
| Phases | **I** | **II** | **III** |
| Primary Treatment Volume | 30 | 00 |  |
| Draining Lymph Nodes | 00 |  |  |
| Treatment Modality | 02 | 00 |  |
| External Beam Planning Technique | 05 |  |  |
| Dose Per Fraction (cGy) | 00200 |  |  |
| Number of Fractions | 030 |  |  |
| Total Dose (cGy) | 006000 |  |  |
| Date RT Started | 2/20/23 | | |
| Date RT Ended | 4/3/23 | | |
| # of Phases of RT to this Volume | 01 | | |
| RT Discontinued Early | 01 | | |
| Total Dose | 006000 | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Case 3 Answer sheet | | | | | | |
| Primary Site | **C34.1** | | Histology | | 8083/3 Basaloid squamous cell carcinoma | |
| AJCC Stage | | | | | | |
| Clinical Stage | cT1b cN0 cM0 Stage 1A2 | | Pathological Stage | | pT2a pN0 cM0 1B | |
| Regional Nodes Positive | | 00 | | | |
| Regional Nodes Examined | | 12 | | | |
| Date Regional Node Dissection | | 11/14/22 | | | |
| Dx Staging and Treatment | | | | | |
| Diagnostic Staging Procedure | | | | 0 | |
| Surgery of Primary Site | | | | A330 | |
| Scope of Regional Lymph Nodes | | | | 5 | |
| Surgical Procedure/Other Site | | | | 0 | |
| Systemic Therapy | | | | | |
| Chemotherapy | | | | 00 | |
| Immunotherapy | | | | 00 | |

|  |  |  |  |
| --- | --- | --- | --- |
| Radiation | | | |
| Phases | **I** | **II** | **III** |
| Primary Treatment Volume | 30 | 00 |  |
| Draining Lymph Nodes | 00 |  |  |
| Treatment Modality | 02 | 00 |  |
| External Beam Planning Technique | 06 |  |  |
| Dose Per Fraction (cGy) | 0800 |  |  |
| Number of Fractions | 005 |  |  |
| Total Dose (cGy) | 004000 |  |  |
| Date RT Started | 11/28/22 | | |
| Date RT Ended | 12/02/23 | | |
| # of Phases of RT to this Volume | 01 | | |
| RT Discontinued Early | 01 | | |
| Total Dose | 004000 | | |